1.Analysis of clinical risk factors of failed electrical cardioversion in patients with persistent atrial fibrillation or atrial flutter
Ki‑Hun KIM ; Ha‑Young CHOI ; Jino PARK ; Yeo‑Jeong SONG ; Seunghwan KIM ; Dong‑Kie KIM ; Sang‑Hoon SEOL ; Doo‑Il KIM ; Pil‑Sung YANG ; Hong Euy LIM ; Junbeum PARK ; Jae‑Min SHIM ; Jinhee AHN ; Sung Ho LEE ; Sung Il IM ; Ju Youn KIM
International Journal of Arrhythmia 2023;24(3):17-
Background:
Although rhythm control could be the best for symptomatic atrial fibrillation (AF), some patients fail to achieve sinus rhythm (SR). This study aimed to identify clinical risk factors of failed electrical cardioversion (ECV).
Methods:
A total of 248 patients who received ECV for persistent AF or atrial flutter (AFL) were retrospectivelyreviewed. Patients were divided into three groups: Group 1 maintained SR for > 1 year, group 2 maintained SR ≤ 1 yearafter ECV, and group 3 failed ECV. SR maintenance was assessed using regular electrocardiography or Holter monitoring.
Results:
Patients were divided into group 1 (73, 29%), group 2 (146, 59%), and group 3 (29, 12%). The mean ageof patients was 60 ± 10 years, and 197 (79%) were male. Age, sex, and baseline characteristics were similar amonggroups. However, increased cardiac size, digoxin use, heart failure (HF), and decreased left ventricular ejection frac‑ tion (LVEF) were more common in group 3. Univariate analysis of clinical risk factors for failed ECV was increasedcardiac size [hazard ratio (HR) 2.14 (95% confidence interval [CI], 1.06–4.34, p = 0.030)], digoxin use [HR 2.66 (95% CI, 1.15–6.14), p = 0.027], HF [HR 2.60 (95% CI, 1.32–5.09), p = 0.005], LVEF < 40% [HR 3.45 (95% CI, 1.00–11.85), p = 0.038], and decreased LVEF [HR 2.49 (95% CI, 1.18–5.25), p = 0.012]. Among them, HF showed clinical significance only by multivariate analysis [HR 3.01 (95% CI, 1.13–7.99), p = 0.027].
Conclusions
Increased cardiac size, digoxin use, HF, LVEF < 40%, and decreased LVEF were related to failed ECV for persistent AF or AFL. Among these, HF was the most important risk factor. Further multi-center studies including greater number of participants are planned.
2.Skin Manifestations Following COVID-19 Vaccination: A Multicenter Case Series Study in Korea
Hee Jung YOON ; Min Jung KWON ; Eun Ji HONG ; Yun Su EUN ; Euy Hyun CHUNG ; Jung Eun KIM ; SangHoon LEE ; Young Lip PARK ; Sul Hee LEE
Korean Journal of Dermatology 2022;60(9):576-584
Background:
During the coronavirus disease 2019 (COVID-19) pandemic, large-scale vaccinations have been performed worldwide without sufficient verification of safety profiles. So far, little is known about skin manifestations following COVID-19 vaccination in Korean patients.
Objective:
We investigated the epidemiological and clinical characteristics of patients who had skin manifestations following COVID-19 vaccination in Korea.
Methods:
We retrospectively reviewed the data of 123 patients that presented with skin manifestations within 1 month after COVID-19 vaccination from two tertiary referral hospitals in Korea. The types of COVID-19 vaccinations administered to the patients, demographics, comorbidities, and clinical course of the patients were obtained from the data. Statistical analyses of the extracted data were performed using Microsoft Excel.
Results:
Skin manifestations following COVID-19 vaccination were mostly observed in patients in their 40s (23.6%), according to our data. Urticarial eruption was the most common manifestation, followed by macular rash (17.1%) and papulosquamous eruption (17.1%). Notably, 70% of the patients showed delayed reactions. More than half of the patients showed a good prognosis, and their symptoms were relieved with conservative treatment, including corticosteroids and antihistamines, even after additional vaccination.
Conclusion
We statistically analyzed the prevalence and characteristics of skin manifestations after COVID-19 vaccination. Urticarial eruptions are the most common skin manifestations associated with the COVID-19 vaccination. We believe that this real-world retrospective study will provide valuable information for doctors who treat patients with skin manifestations after COVID-19 vaccination by providing real-world experience in Korea.
3.Risk Factors for Requiring Glaucoma Surgery in Steroid-induced Glaucoma
Doh Hoon CHUNG ; Kyung Euy HONG ; Hae-Young Lopilly PARK
Journal of the Korean Ophthalmological Society 2021;62(1):91-99
Purpose:
To study the risk factors for steroid-induced glaucoma patients requiring glaucoma surgery, despite being fully treated with medications and laser trabeculoplasty.
Methods:
The charts of 50 eyes diagnosed with steroid-induced glaucoma from January 2012 to December 2015 were reviewed retrospectively. 28 eyes required surgery and 22 eyes were successfully treated with medications and laser trabeculoplasty. The demographic information as well as ocular parameters, presence of ocular/systemic comorbidities, and past history of steroid use were evaluated to determine the risk factors associated with the need for glaucoma surgery.
Results:
For the 7 factors that were statistically significant by univariate regression analysis, multivariate regression analysis showed that the average retinal nerve fiber layer thickness and duration of steroid use were not statistically significant (p = 0.876 and p = 0.068, respectively), whereas age and initial intraocular pressure were only statistically significant in some of the analysis models (p = 0.040-0.278, p = 0.016-0.201, respectively). Myopia, vertical cup-to-disc ratio, and systemic comorbidities had statistically significant correlations (p = 0.019, p = 0.011-0.03, p = 0.022, respectively) with surgical decision by multivariate regression analysis.
Conclusions
The risk factors for requiring glaucoma surgery in steroid-induced glaucoma patients were young age, myopia, initial optic nerve damage, systemic disease (systemic lupus erythematosus, rheumatoid arthritis, and atopy), and duration of steroid use. These results may be helpful in predicting the prognosis of patients with steroid-induced glaucoma and in screening for patients who require a more aggressive treatment at the time of disease presentation.
4.A Case Report of Hailey–Hailey Disease Treated with Alitretinoin
A Young PARK ; Ho Jung LEE ; Euy Hyun CHUNG ; Jung Eun KIM ; Jong Suk LEE ; Sang Hoon LEE ; Sung Yul LEE
Annals of Dermatology 2019;31(Suppl):S1-S2
No abstract available.
5.A Case Report of Hailey–Hailey Disease Treated with Alitretinoin
A Young PARK ; Ho Jung LEE ; Euy Hyun CHUNG ; Jung Eun KIM ; Jong Suk LEE ; Sang Hoon LEE ; Sung Yul LEE
Annals of Dermatology 2019;31(Suppl 1):S1-S2
6.2018 Korean Guideline of Atrial Fibrillation Management
Boyoung JOUNG ; Jung Myung LEE ; Ki Hong LEE ; Tae Hoon KIM ; Eue Keun CHOI ; Woo Hyun LIM ; Ki Woon KANG ; Jaemin SHIM ; Hong Euy LIM ; Junbeom PARK ; So Ryoung LEE ; Young Soo LEE ; Jin Bae KIM ;
Korean Circulation Journal 2018;48(12):1033-1080
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population. The Korean Heart Rhythm Society organized a Korean AF Management Guideline Committee and analyzed all available studies regarding the management of AF, including studies on Korean patients. This guideline is based on recent data of the Korean population and the recent guidelines of the European Society of Cardiology, European Association for Cardio-Thoracic Surgery, American Heart Association, and Asia Pacific Heart Rhythm Society. Expert consensus or guidelines for the optimal management of Korean patients with AF were achieved after a systematic review with intensive discussion. This article provides general principles for appropriate risk stratification and selection of anticoagulation therapy in Korean patients with AF. This guideline deals with optimal stroke prevention, screening, rate and rhythm control, risk factor management, and integrated management of AF.
American Heart Association
;
Anticoagulants
;
Arrhythmias, Cardiac
;
Asia
;
Atrial Fibrillation
;
Cardiology
;
Consensus
;
Heart
;
Humans
;
Mass Screening
;
Risk Factors
;
Stroke
7.Five-Year Outcomes of Successful Percutaneous Coronary Intervention with Drug-Eluting Stents versus Medical Therapy for Chronic Total Occlusions.
Seung Woon RHA ; Byoung Geol CHOI ; Man Jong BAEK ; Yang gi RYU ; Hu LI ; Se Yeon CHOI ; Jae Kyeong BYUN ; Ahmed MASHALY ; Yoonjee PARK ; Won Young JANG ; Woohyeun KIM ; Jah Yeon CHOI ; Eun Jin PARK ; Jin Oh NA ; Cheol Ung CHOI ; Hong Euy LIM ; Eung Ju KIM ; Chang Gyu PARK ; Hong Seog SEO ; Dong Joo OH
Yonsei Medical Journal 2018;59(5):602-610
PURPOSE: Many recent studies have reported that successful percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) for chronic total occlusion (CTO) has more beneficial effects than failed CTO-PCI; however, there are only limited data available from comparisons of successful CTO-PCI with medical therapy (MT) in the Korean population. MATERIALS AND METHODS: A total of 840 consecutive CTO patients who underwent diagnostic coronary angiography, receiving either PCI with DESs or MT, were enrolled. Patients were divided into two groups according to the treatment assigned. To adjust for potential confounders, propensity score matching (PSM) analysis was performed using logistic regression. Individual major clinical outcomes and major adverse cardiac events, a composite of total death, myocardial infarction (MI), stroke, and revascularization, were compared between the two groups up to 5 years. RESULTS: After PSM, two propensity-matched groups (265 pairs, n=530) were generated, and the baseline characteristics were balanced. Although the PCI group showed a higher incidence of target lesion and vessel revascularization on CTO, the incidence of MI tended to be lower [hazard ratio (HR): 0.339, 95% confidence interval (CI): 0.110 to 1.043, p=0.059] and the composite of total death or MI was lower (HR: 0.454, 95% CI: 0.224 to 0.919, p=0.028), compared with the MT group up to 5 years. CONCLUSION: In this study, successful CTO PCI with DESs was associated with a higher risk of repeat PCI for the target vessel, but showed a reduced incidence of death or MI.
Coronary Angiography
;
Drug-Eluting Stents*
;
Humans
;
Incidence
;
Logistic Models
;
Myocardial Infarction
;
Percutaneous Coronary Intervention*
;
Propensity Score
;
Stroke
8.2018 Korean Guideline of Atrial Fibrillation Management
Boyoung JOUNG ; Jung Myung LEE ; Ki Hong LEE ; Tae Hoon KIM ; Eue Keun CHOI ; Woo Hyun LIM ; Ki Woon KANG ; Jaemin SHIM ; Hong Euy LIM ; Junbeom PARK ; So Ryoung LEE ; Young Soo LEE ; Jin Bae KIM ;
Korean Circulation Journal 2018;48(12):1033-1080
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population. The Korean Heart Rhythm Society organized a Korean AF Management Guideline Committee and analyzed all available studies regarding the management of AF, including studies on Korean patients. This guideline is based on recent data of the Korean population and the recent guidelines of the European Society of Cardiology, European Association for Cardio-Thoracic Surgery, American Heart Association, and Asia Pacific Heart Rhythm Society. Expert consensus or guidelines for the optimal management of Korean patients with AF were achieved after a systematic review with intensive discussion. This article provides general principles for appropriate risk stratification and selection of anticoagulation therapy in Korean patients with AF. This guideline deals with optimal stroke prevention, screening, rate and rhythm control, risk factor management, and integrated management of AF.
9.Routine Angiographic Follow-Up versus Clinical Follow-Up after Percutaneous Coronary Intervention in Acute Myocardial Infarction.
Yong Hoon KIM ; Ae Young HER ; Seung Woon RHA ; Byoung Geol CHOI ; Minsuk SHIM ; Se Yeon CHOI ; Jae Kyeong BYUN ; Hu LI ; Woohyeun KIM ; Jun Hyuk KANG ; Jah Yeon CHOI ; Eun Jin PARK ; Sung Hun PARK ; Sunki LEE ; Jin Oh NA ; Cheol Ung CHOI ; Hong Euy LIM ; Eung Ju KIM ; Chang Gyu PARK ; Hong Seog SEO ; Dong Joo OH
Yonsei Medical Journal 2017;58(4):720-730
PURPOSE: Differences in the utility of routine angiographic follow-up (RAF) and clinical follow-up (CF) after percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are not well understood. The present study aimed to compare the 3-year clinical outcomes of RAF and CF in AMI patients who underwent PCI with drug-eluting stents (DES). MATERIALS AND METHODS: A total of 774 consecutive AMI patients who underwent PCI with DES were enrolled. RAF was performed at 6 to 9 months after index PCI (n=425). The remaining patients were medically managed and clinically followed (n=349); symptom-driven events were captured. To adjust for any potential confounders, a propensity score matched analysis was performed using a logistic regression model, and two propensity-matched groups (248 pairs, n=496, C-statistic=0.739) were generated. Cumulative clinical outcomes up to 3 years were compared between RAF and CF groups. RESULTS: During the 3-year follow-up period, the cumulative incidences of revascularization [target lesion revascularization: hazard ratio (HR), 2.40; 95% confidence interval (CI), 1.18–4.85; p=0.015, target vessel revascularization (TVR): HR, 3.33; 95% CI, 1.69–6.58; p=0.001, non-TVR: HR, 5.64; 95% CI, 1.90–16.6; p=0.002] and major adverse cardiac events (MACE; HR, 3.32; 95% CI, 1.92–5.73; p<0.001) were significantly higher in the RAF group than the CF group. However, the 3-year incidences of death and myocardial infarction were not different between the two groups. CONCLUSION: RAF following index PCI with DES in AMI patients was associated with increased incidences of revascularization and MACE. Therefore, CF seems warranted for asymptomatic patients after PCI for AMI.
Coronary Angiography
;
Drug-Eluting Stents
;
Follow-Up Studies*
;
Humans
;
Incidence
;
Logistic Models
;
Myocardial Infarction*
;
Percutaneous Coronary Intervention*
;
Propensity Score
10.Impact of Diltiazem Alone versus Diltiazem with Nitrate on Five-Year Clinical Outcomes in Patients with Significant Coronary Artery Spasm.
Taeshik PARK ; Ji Young PARK ; Seung Woon RHA ; Hong Seog SEO ; Byoung Geol CHOI ; Se Yeon CHOI ; Jae Kyeong BYUN ; Sang Ho PARK ; Eun Jin PARK ; Jah Yeon CHOI ; Sung Hun PARK ; Jae Joong LEE ; Sunki LEE ; Jin Oh NA ; Cheol Ung CHOI ; Hong Euy LIM ; Jin Won KIM ; Eung Ju KIM ; Chang Gyu PARK ; Dong Joo OH
Yonsei Medical Journal 2017;58(1):90-98
PURPOSE: Calcium channel blockers diltiazem and nitrate have been used as selective coronary vasodilators for patients with significant coronary artery spasm (CAS). However, no study has compared the efficacy of diltiazem alone versus diltiazem with nitrate for long-term clinical outcomes in patients with CAS. MATERIALS AND METHODS: A total of 2741 consecutive patients without significant coronary artery disease with positive CAS by acetylcholine (Ach) provocation test between November 2004 and May 2014 were enrolled. Significant CAS was defined as a narrowing of >70% by incremental intracoronary injection of 20, 50, and 100 µg of Ach into the left coronary artery. Patients were assigned to either the diltiazem group (n=842) or the dual group (diltiazem with nitrate, n=1899) at physician discretion. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM analysis, two well-balanced groups (811 pairs, n=1622, C-statistic=0.708) were generated. RESULTS: At 5 years, there were similar incidences in primary endpoints, including mortality, myocardial infarction, revascularization, and recurrent angina requiring repeat coronary angiography between the two groups. Diltiazem alone was not an independent predictor for major adverse cardiovascular events or recurrent angina requiring repeat coronary angiography. CONCLUSION: Despite the expected improvement of endothelial function and the relief of CAS, the combination of diltiazem and nitrate treatment was not superior to diltiazem alone in reducing mortality and cardiovascular events up to 5 years in patients with significant CAS.
Acetylcholine
;
Aged
;
Angina Pectoris/diagnosis
;
Calcium Channel Blockers/therapeutic use
;
Cardiovascular Agents/*therapeutic use
;
Coronary Angiography/adverse effects
;
Coronary Artery Disease/prevention & control
;
Coronary Vasospasm/diagnosis/*drug therapy
;
Diltiazem/*therapeutic use
;
Drug Therapy, Combination
;
Female
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Myocardial Infarction/prevention & control
;
Nitrates/*therapeutic use
;
Propensity Score
;
Time Factors
;
Vasodilator Agents/therapeutic use

Result Analysis
Print
Save
E-mail